Product Description
Mechanisms of Action: CDH3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocity Biopharmaceutics Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BC3195-102 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-04-30 |
|
| BC3195 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-06-01 |
|
| CTR20231334 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |